Clinical trials: sponsored by The Netherlands Cancer Institute
Mesotheliomas Pleural
Pembrolizumab Plus Lenvatinib In Second Line and Third Line Malignant Pleural mesotheLioma Patients
There is no standard second line treatment in malignant pleural mesothelioma (MPM). Pembrolizumab has shown to be active in in small phase II studies in MPM. Its activity however, is limited, with a response rate up to 20%.
- Trial name
- PEMMELA (NCT04287829)
- Testing
- Pembrolizumab, Lenvatinib
- Where
- Netherlands
- Volunteers
- 58 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Monalizumab and Trastuzumab In Metastatic HER2-pOSitive breAst Cancer: MIMOSA-trial
In this phase II clinical trial the efficacy of the combination of monalizumab and trastuzumab is assessed in patients with metastatic or locally incurable HER2-positive breast cancer
- Trial name
- MIMOSA (NCT04307329)
- Testing
- Monalizumab, Trastuzumab
- Where
- Netherlands
- Volunteers
- 12 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer, Prostate Cancer Metastatic
The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate Cancer
This study aims to investigate the diagnostic value of FAPI PET/CT, relative to standard-of-care imaging using PSMA PET/CT, in staging of newly diagnosed PCa.
- Trial name
- proFAPI (NCT06634173)
- Testing
- FAPI PET/CT
- Volunteers
- 30 people
- Sponsor
- The Netherlands Cancer Institute
Metastatic Breast Cancer
NOvel Immunotherapy Strategies for Advanced Triple Negative Breast Cancer (TNBC) Patients: TONIC-3 Trial
This is a single center, non-blinded, multi-cohort, non-comparative phase II trial to study the safety and efficacy of tiragolumab with atezolizumab and/or ipilimumab in advanced triple-negative breast cancer.
- Trial name
- TONIC-3 (NCT06342037)
- Testing
- Tiragolumab, Atezolizumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 60 people
- Sponsor
- The Netherlands Cancer Institute
Prostate Cancer
Multispectral Fluorescence as a Tool to Separate Healthy and Disease Related Lymphatic Anatomies in Prostate Cancer.
Multispectral imaging of the lymphatic draining pattern of the tumor and the abdominall wall/lower limb to evaluate technical feasibility to differentiate these patterns and in the future reduce the amount of complications that…
- Trial name
- SPLIT (NCT05120973)
- Testing
- multispectral imaging, fluorescence for lymphatic mapping
- Where
- Netherlands
- Volunteers
- 26 people
- Sponsor
- The Netherlands Cancer Institute
Head and Neck Cancer, Oral Cancer
Improved Implant for Reconstruction Purposes After Mandibular Resection
Study design: A single center non-randomized, prospective clinical feasibility study. Study population: Study population is composed of 10 patients ineligible for a free-flap bone reconstruction.
- Trial name
- RifRam (NCT05153733)
- Testing
- RIFRAM implant
- Where
- Netherlands
- Volunteers
- 3 people, healthy volunteers welcome
- Sponsor
- The Netherlands Cancer Institute
Soft Tissue Sarcoma, Xenograft Model
A Platform of Patient Derived Xenografts (PDX) and 2D/3D Cell Cultures of Soft Tissue Sarcomas (STS)
Outside the setting of well-designed prospective clinical studies, the current standard preoperative RT should be a conventionally 1.8-2 Gy fractionated regimen to a total dose of 50 Gy in 5-6 weeks.
- Conditions
- Soft Tissue Sarcoma, Xenograft Model, 2D/3D Cell Cultures
- Trial name
- SarcomaPDX (NCT02910895)
- Testing
- tumor biopsy
- Where
- Netherlands
- Volunteers
- 40 people
- Sponsor
- The Netherlands Cancer Institute
Prostatic Neoplasms
Oral Docetaxel (ModraDoc/r) in Combination With Hormonal Treatment and Radiation Therapy in High-risk Prostate Cancer
The optimal treatment for HRPC patients has not yet been established. Recent trials suggest a benefit from early treatment with docetaxel in the castration-sensitive setting, with an improvement in failure free survival in high…
- Trial name
- DOP (NCT03066154)
- Testing
- oral docetaxel (ModraDoc/r), androgen deprivation therapy, high-dose intensity-modulated radiation therapy
- Where
- Netherlands
- Volunteers
- 24 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Pre-operative Trial for Breast Cancer With Nivolumab in Combination With Novel IO
To determine whether short-term pre-operative nivolumab either as monotherapy or in combination with low dose doxorubicin or novel IO combinations can induce immune activation in early BC.
- Trial name
- BELLINI (NCT03815890)
- Testing
- Nivolumab, Ipilimumab
- Where
- Netherlands
- Volunteers
- 80 people
- Sponsor
- The Netherlands Cancer Institute
Ovarian Cancer Stage IV, Peritoneal Cancer
Neo-adjuvant Pembrolizumab in Primary Stage IV Ovarian Cancer
This is a single arm feasibility study in patients with primary FIGO stage IV serous ovarian, peritoneal, or fallopian tube cancer to evaluate neo-adjuvant + adjuvant pembrolizumab for its capacity to induce and broaden T cell…
- Conditions
- Ovarian Cancer Stage IV, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- NCT03126812
- Testing
- Carboplatin, Paclitaxel, Pembrolizumab
- Where
- Netherlands
- Volunteers
- 33 people
- Sponsor
- The Netherlands Cancer Institute
Gastric Cancer
Multicentric Randomised Trial for Resectable Gastric Cancer
The CRITICS-II trial aims to identify the optimal preoperative regimen in resectable gastric cancer by comparing three investigational treatment arms: chemotherapy vs. chemotherapy and subsequent chemoradiotherapy vs.
- Trial name
- CRITICS-II (NCT02931890)
- Testing
- Docetaxel, Oxaliplatin, Capecitabine
- Where
- 28 sites in Netherlands
- Volunteers
- 207 people
- Sponsor
- The Netherlands Cancer Institute
Locally Advanced Vulvar Carcinoma, Squamous Cell Carcinoma of the Vulva
Primary Chemoradiation VS. Neoadjuvant Chemotherapy Followed By Surgery As Treatment Strategy For LAVC
A phase 2 randomised controlled trial will be performed in which the efficacy and safety of standard treatment (primary chemoradiation; consisting of 64.5 Gy in 30 fractions of external beam radiotherapy with weekly cisplatin for…
- Trial name
- VULCANIZE-II (NCT05905315)
- Testing
- Paclitaxel and Carboplatin, Chemoradiation
- Where
- 2 sites in Netherlands
- Volunteers
- 98 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer, HER2 Positive
Neoadjuvant Chemotherapy in HER2 Positive Breast Cancer, TRAIN-2
This study compares two schedules of upfront chemotherapy in HER positive breast cancer.
- Trial name
- TRAIN-2 (NCT01996267)
- Testing
- PTC+Pertuzumab, FEC-T+Pertuzumab
- Where
- 33 sites in Netherlands
- Volunteers
- 437 people
- Sponsor
- The Netherlands Cancer Institute
NSCLC
Distributed Learning of Edic and CardIac Dose Effects in Lung Cancer
Cardiac dose was not a major concern in lung radiotherapy patients until the results of the RTOG (Radiation Therapy Oncology Group) 0617 trial, which showed an association between cardiac dose and survival.
- Trial name
- DECIDE (NCT06329648)
- Volunteers
- 20,000 people
- Sponsor
- The Netherlands Cancer Institute
Urothelial Carcinoma, Bladder Cancer
Checkpoint Inhibition and Chemoradiotherapy as Bladder Sparing Treatment in UC
This is a single-armed, multicenter, non-blinded phase 2 study to assess efficacy of induction ipilimumab + nivolumab followed by chemoradiation to spare the bladder in urothelial bladder cancer.
- Trial name
- Indi-Blade (NCT05200988)
- Testing
- Ipilimumab + nivolumab
- Where
- 3 sites in Netherlands
- Volunteers
- 50 people
- Sponsor
- The Netherlands Cancer Institute
Malignant Melanoma Stage III
Neoadjuvant Ipilimumab Plus Nivolumab Versus Standard Adjuvant Nivolumab in Macroscopic Stage III Melanoma
This is an international (Australia, Europe, and USA) open-label two-arm randomized phase 3 trial including 420 stage III (≤3 resectable in-transit metastases allowed) cutaneous or unknown primary melanoma patients.
- Trial name
- NADINA (NCT04949113)
- Testing
- Neoadjuvant ipilimumab + nivolumab, Adjuvant nivolumab
- Where
- 24 sites in United States, Australia and 1 more
- Volunteers
- 423 people
- Sponsor
- The Netherlands Cancer Institute
Tumors at All Sites Which Will Receive Radiotherapy
The MR-Linac Technical Feasibility Protocol
Radiation therapy is predominantly based on a Computed Tomography (CT) scan obtained during the treatment planning phase. During the course of radiotherapy, however, both the tumor and organs at risk (OAR) are variable in…
- Trial name
- UMBRELLA-II (NCT04351204)
- Testing
- radiotherapy
- Where
- Netherlands
- Volunteers
- 140 people
- Sponsor
- The Netherlands Cancer Institute
Carcinoma, Squamous Cell of Head and Neck
ctDNA as a Biomarker for Treatment Response in HNSCC
Tumours continually shed DNA into the circulation, where it can be accessed. This circulating tumour DNA (ctDNA) directly reflects tumour burden and has great potential to be a sensitive biomarker for treatment recurrence.
- Trial name
- PECAN (NCT03540563)
- Testing
- Blood draw
- Where
- Netherlands
- Volunteers
- 70 people
- Sponsor
- The Netherlands Cancer Institute
Cancer, Tumors
The Drug Rediscovery Protocol (DRUP Trial)
This is a prospective, non-randomized clinical trial that aims to describe the efficacy and toxicity of commercially available, targeted anticancer drugs* prescribed for treatment of patients with advanced cancer with a…
- Conditions
- Cancer, Tumors, Neoplasm, Neoplasia
- Trial name
- DRUP (NCT02925234)
- Testing
- Panitumumab, Olaparib, Dabrafenib
- Where
- 36 sites in Netherlands
- Volunteers
- 1,550 people
- Sponsor
- The Netherlands Cancer Institute
Breast Cancer
Neoadjuvant Trastuzumab, Pertuzumab and Tucatinib Without Chemotherapy in HER2-positive Breast Cancer: the TRAIN-4 Study
This is a single-center, phase 1b study evaluating the safety and feasibility of a neoadjuvant treatment with tucatinib, trastuzumab and pertuzumab in stage II-IIIA HER2-positive breast cancer.
- Trial name
- TRAIN-4 (NCT06162559)
- Testing
- Tucatinib, Trastuzumab, Pertuzumab
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- The Netherlands Cancer Institute